Axsome Therapeutics Announces Closing of Public Offering of $225 Million of Shares of Common Stock
30 juin 2023 16h02 HE
|
Axsome Therapeutics, Inc.
NEW YORK, June 30, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the...
Axsome Therapeutics Announces Pricing of Public Offering of $225 Million of Shares of Common Stock
28 juin 2023 09h28 HE
|
Axsome Therapeutics, Inc.
NEW YORK, June 28, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing and delivering novel therapies for the...
Axsome Therapeutics Announces Proposed Public Offering of Common Stock
27 juin 2023 20h24 HE
|
Axsome Therapeutics, Inc.
NEW YORK, June 27, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (“Axsome” or the “Company”), a biopharmaceutical company developing novel therapies for the management of central...
Axsome Therapeutics to Present New Sunosi® Data at SLEEP 2023
01 juin 2023 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, June 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present Data and Post-Hoc Analyses on Auvelity® and Sunosi® at the 2023 American Society of Clinical Psychopharmacology (ASCP) Annual Meeting
30 mai 2023 07h00 HE
|
Axsome Therapeutics, Inc.
Data on Auvelity demonstrating improved functioning in major depressive disorder Data on Sunosi demonstrating improved cognitive function in patients with excessive daytime sleepiness associated with...
Axsome Therapeutics Reports First Quarter 2023 Financial Results and Corporate Update
08 mai 2023 07h00 HE
|
Axsome Therapeutics, Inc.
Auvelity® 1Q 2023 net product sales of $15.7 million Total 1Q 2023 net product sales of $28.6 million Total 1Q 2023 revenue of $94.6 million, including Sunosi® ex-U.S. license agreement upfront...
Axsome Therapeutics to Present at the Bank of America Securities 2023 Healthcare Conference
03 mai 2023 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 03, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics Joins Mental Health America and the State of New York to Raise Awareness of Mental Health During May is Mental Health Month
01 mai 2023 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, May 01, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present Five Abstracts Including New Data from the Positive SHARP Study of SUNOSI® (solriamfetol) in Participants with Cognitive Impairment with Excessive Daytime Sleepiness in Obstructive Sleep Apnea at the 2023 American Academy of Neurology (AAN) Annual Meeting
21 avr. 2023 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, April 21, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...
Axsome Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference
14 avr. 2023 07h00 HE
|
Axsome Therapeutics, Inc.
NEW YORK, April 14, 2023 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company developing and delivering novel therapies for the management of central nervous...